The key change is that GMP inspection outcomes will become publicly visible, rather than remaining information communicated primarily between the TGA and the inspected manufacturer.
Recognising that some organisations may require additional time to complete implementation, the TGA has introduced a streamlined UDI Consent to Supply process commencing on 1 July 2026.
The TGA compliance principles are grounded in scientific rigor, risk-based thinking, and lifecycle control of therapeutic goods.
Therapeutic goods manufacturers face a complex and evolving regulatory landscape, with challenges spanning quality management, data integrity, validation, and supply chain oversight. While these challenges are diverse, they share a common underlying cause: insufficient visibility and control at the system level.